Exceptional response to cyclophosphamide and dexamethasone in a patient with metastatic castrate-resistant prostate cancer and RB1 mutation-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Exceptional response to cyclophosphamide and dexamethasone in a patient with metastatic castrate-resistant prostate cancer and RB1 mutation

Published:2020-12-18 Issue:3 Volume:32 Page:337-343
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:

Author:

Dohogne Briana,Arif-Tiwari Hina,Bracamonte Erika,Babiker Hani M.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference15 articles.

1. Cancer statistics.;Siegel;Am Cancer Soc,2020

2. Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy.;Nelius;Med Oncol,2010

3. RB1 heterogeneity in advanced metastatic castration-resistant prostate cancer.;Nava Rodrigues;Clin Cancer Res,2019

4. Alterations in the RB1 gene and outcomes in metastatic castration-resistant prostate cancer;The ASCO Post

5. Oral low-dose cyclophosphamide in metastatic hormone refractory prostate cancer (MHRPC).;Nicolini;Biomed Pharmacother,2004

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular tests for prediction of tumor sensitivity to cytotoxic drugs;Cancer Letters;2022-02

2. Antineoplastics;Reactions Weekly;2022-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP